Dougherty & Co restated their buy rating on shares of BioTelemetry (NASDAQ:BEAT) in a research report sent to investors on Friday morning, Briefing.com Automated Import reports. The firm currently has a $75.00 target price on the medical research company’s stock, down from their prior target price of $81.00. Dougherty & Co also issued estimates for BioTelemetry’s Q2 2019 earnings at $0.46 EPS and FY2020 earnings at $2.20 EPS.
Other research analysts have also recently issued reports about the company. Benchmark set a $82.00 price target on BioTelemetry and gave the company a buy rating in a research note on Tuesday, April 2nd. ValuEngine cut BioTelemetry from a buy rating to a hold rating in a research note on Monday, April 1st. Zacks Investment Research cut BioTelemetry from a buy rating to a hold rating in a research note on Tuesday, February 12th. BidaskClub upgraded BioTelemetry from a buy rating to a strong-buy rating in a research note on Friday, January 11th. Finally, Sidoti set a $95.00 price target on BioTelemetry and gave the company a buy rating in a research note on Tuesday, February 5th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. BioTelemetry has a consensus rating of Buy and a consensus target price of $79.57.
NASDAQ BEAT opened at $56.93 on Friday. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.96 and a quick ratio of 2.81. BioTelemetry has a fifty-two week low of $37.70 and a fifty-two week high of $80.92. The firm has a market cap of $1.92 billion, a price-to-earnings ratio of 29.35 and a beta of 1.43.
BioTelemetry (NASDAQ:BEAT) last released its earnings results on Thursday, April 25th. The medical research company reported $0.42 earnings per share for the quarter, hitting the consensus estimate of $0.42. BioTelemetry had a return on equity of 24.15% and a net margin of 11.86%. The firm had revenue of $103.98 million during the quarter, compared to analysts’ expectations of $104.17 million. During the same period in the prior year, the company earned $0.39 earnings per share. The company’s quarterly revenue was up 10.0% on a year-over-year basis. As a group, analysts predict that BioTelemetry will post 1.99 EPS for the current fiscal year.
In related news, VP Heather C. Getz sold 93,383 shares of the firm’s stock in a transaction on Tuesday, January 29th. The stock was sold at an average price of $70.06, for a total transaction of $6,542,412.98. Following the completion of the transaction, the vice president now directly owns 119,085 shares of the company’s stock, valued at approximately $8,343,095.10. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Heather C. Getz sold 10,590 shares of the firm’s stock in a transaction on Friday, February 1st. The stock was sold at an average price of $70.41, for a total value of $745,641.90. Following the transaction, the vice president now directly owns 80,661 shares of the company’s stock, valued at $5,679,341.01. The disclosure for this sale can be found here. 6.50% of the stock is currently owned by corporate insiders.
Large investors have recently made changes to their positions in the stock. Financial Architects Inc bought a new position in BioTelemetry during the 4th quarter worth $30,000. Huntington National Bank raised its position in BioTelemetry by 35.5% during the 1st quarter. Huntington National Bank now owns 680 shares of the medical research company’s stock worth $43,000 after purchasing an additional 178 shares during the last quarter. We Are One Seven LLC bought a new position in BioTelemetry during the 4th quarter worth $44,000. Ropes Wealth Advisors LLC bought a new position in BioTelemetry during the 1st quarter worth $50,000. Finally, First Financial Corp IN acquired a new stake in BioTelemetry during the 1st quarter worth about $63,000. 88.57% of the stock is owned by institutional investors and hedge funds.
BioTelemetry, Inc, a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core lab services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in Healthcare, Research, and Corporate and Other segments.
Recommended Story: Understanding Stock Ratings
Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.